Clinical Evaluation of GRAPE Model for Gastric Cancer Screening

NCT07067983 · tracked via the Priya Life Science China tracker

Sponsor

Zhejiang Cancer Hospital

Phase

Observational

Started

2025-05-30

Last updated

2025-07-16

Condition(s) studied

Gastric Cancer

Investigational drug(s) / intervention(s)

Results following systematic screening

Results following systematic screening: The GRAPE model's output (positive or negative) determines whether patients require follow-up gastroscopy

Study summary

A Prospective Study Evaluating the Performance of the GRAPE Model in Gastric Cancer Screening and Its Detection Rates Across Different Disease Stages

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Accepted

Inclusion Criteria: * Aged between 18 and 80 years * Individuals undergoing thoracoabdominal CT examination * Voluntarily participated in the study and provided written informed consent Exclusion Criteria: * Patients with confirmed diagnosis of gastric cancer * Individuals with severe intellectual disabilities or communication disorders

Primary outcome measure(s)

GRAPE systematic screening results — first visited at baseline
Screen-positive individuals after GRAPE systematic screening

Trial sites (1)

Facility	City	Region	Status
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)	Hangzhou	Zhejiang	Recruiting

More Zhejiang Cancer Hospital trials in China

IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer Recruiting

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma Recruiting

Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma Starting soon

Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer Active, not recruiting

SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC Recruiting

Other trials for the same condition

Research on Early Recurrence of Locally Advanced Gastric Cancer Based on CT Radiomics Prediction Enrolling by invitation

the Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer Starting soon

Novel Humanized Ferritin-Based NIR Fluorescent Probe for Identifying Sentinel Lymph Node Metastasis in Early Gastric Cancer Recruiting

Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease Recruiting

Gastric Cancer Marker Detection and Its Kit Development Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07067983 on ClinicalTrials.gov ↗ ← All trials in China